Cancer Tests, GLP-One Growth, Vaccine Demands

Kilder

• STAT: STAT+: Lilly’s breast cancer combo wins approval
• STAT: STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
• Thestate: Grail rallies as FDA staff flags no major concerns for multi-cancer test - The State
• Scanx: Grail stock surges 36% on positive FDA briefing docs for Galleri test - scanx.trade
• Beckershospitalreview: Lilly captures 70% of new Medicare GLP-1 patients, CEO says
• Suaragarut: Eli Lilly Captures 70% of New Medicare GLP-1 Patients - SuaraGarut.ID
• CNBC: Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs - CNBC
• Tradingview: Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets - tradingview.com
• Kff: Overview of Health Coverage and Care for Individuals with Limited English Proficiency (LEP)
• STAT: STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
• Raps: Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert control over NIH grant funding - RAPS
• Newsquawk: JPMorgan (JPM) is reportedly looking to target a USD 20bln investment partnership with Qatar's QIA, Bloomberg reports - Newsquawk
• STAT: President Trump’s newest vaccine ‘demands’ repeat old misinformation
• Ua: Trump announces new vaccine demands — STAT News - UA.NEWS

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.